Arcutis logo.png
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
09 mars 2023 08h00 HE | Arcutis Biotherapeutics, Inc.
Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitisNew national survey insights depicting disease burden, path to diagnosis...